Merkel Cell Carcinoma Clinical Trial
Official title:
Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
This phase II trial tests whether hypofractionated radiation works to treat patients with Merkel cell carcinoma. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a fewer number of days than tradition radiation therapy courses for Merkel cell carcinoma. This may be less suppressive of the immune response to tumors and should be helpful for patient convenience.
- To estimate the 2-year local control rate for adjuvant hypofractionated RT to the primary tumor bed. - To estimate the 2-year nodal control rate for adjuvant hypofractionated RT to the primary draining nodal basin. Secondary Objectives - To determine MCC disease outcomes including:time to non-nodal locoregional recurrence, time to nodal recurrence, time to distant mestasis, disease-free-survival and disease-specific survival for patients receiving hypofractionated adjuvant RT. - To assess acute and late RT associated toxicity within or neighboring the radiated field. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT02978625 -
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
|
Phase 2 | |
| Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
| Not yet recruiting |
NCT04705389 -
SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines
|
N/A | |
| Recruiting |
NCT03212404 -
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
|
Phase 1 | |
| Recruiting |
NCT05429866 -
Immunological Variables Associated to ICI Toxicity in Cancer Patients
|
Phase 2 | |
| Completed |
NCT03545334 -
Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study
|
N/A | |
| Recruiting |
NCT04260802 -
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04291885 -
Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma
|
Phase 2 | |
| Terminated |
NCT02054884 -
F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT04975152 -
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
|
Phase 1 | |
| Not yet recruiting |
NCT06039033 -
Exploring Merkel Cell Carcinoma Clinical Trial Engagement Patterns
|
||
| Completed |
NCT02514824 -
MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
|
Phase 1/Phase 2 | |
| Completed |
NCT04393753 -
Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1
|
Phase 2 | |
| Recruiting |
NCT06056895 -
Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT03370861 -
How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes
|
||
| Suspended |
NCT04916002 -
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
|
Phase 2 | |
| Recruiting |
NCT03210935 -
French National Database of Rare Dermatological Cancers
|
||
| Active, not recruiting |
NCT04116320 -
Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06086288 -
Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC)
|
Phase 2 |